The Slowest Emergency

Cardiovascular disease is the leading cause of death worldwide, and yet it is also one of the most preventable. The reason for both facts is the same. Heart attacks and most strokes are the end point of atherosclerosis, a process that builds quietly over decades in which fatty deposits called plaque slowly collect inside the walls of your arteries. Because the damage is slow and cumulative, there is a long window in which it can be slowed. Prevention here is not a single dramatic act. It is the steady lowering of risk, year after year.

What actually goes wrong

The central player is low-density lipoprotein, or LDL, the kind usually called "bad cholesterol." It carries cholesterol through the blood, and when there is too much of it for too long, it lodges in artery walls and drives the growth of plaque. Over time a plaque can narrow an artery or rupture, triggering a clot that blocks blood flow. When that happens in the heart it is a heart attack. When it happens in the brain it is a stroke.

The key idea is exposure over time. It is not only how high your LDL is today, but how high it has been across your whole life. Doctors call this cumulative LDL burden, meaning the total dose of cholesterol your arteries have absorbed across a lifetime.1 It also explains why prevention started earlier tends to matter more than prevention started late.

Lowering LDL early is one of the few interventions that behaves, in practice, like slowing aging itself.

From daily pills to durable protection

For decades the workhorse of prevention has been the statin, a daily pill that lowers LDL and has a large, well-established record of preventing heart attacks. Statins remain foundational. What is new is the move toward protection that does not depend on remembering a pill every day.

A protein called PCSK9 acts like a brake on the liver's ability to pull LDL out of the blood. People born with naturally low PCSK9 activity tend to have low LDL and low heart disease risk across their entire lives, which makes it an appealing target. First came antibody drugs that block PCSK9. Then came inclisiran, which uses RNA interference, a technique that switches a gene down rather than blocking the protein it makes. It is given as an injection roughly twice a year instead of a daily pill. Approved2 The direction of travel is clear. Therapies are starting to behave less like daily maintenance and more like an occasional update.

The frontier: editing risk out once

The most ambitious version of this idea is gene editing. Base editing, which changes a single letter of DNA without cutting the strand, has been used in early trials to switch off PCSK9 in the liver, producing large LDL reductions from a single treatment. In trials34 This is genuinely early work, and it has already run into real safety questions, which is a reminder that "durable" must never come to mean an irreversible mistake. But the concept is no longer science fiction. A one-time intervention that compresses decades of daily prevention into a single step is now something researchers are actively testing.